Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

T. Nishi



Author of

  • +

    P1.08 - Poster Session/ Thymoma, Mesothelioma and Other Thoracic Malignancies (ID 224)

    • Event: WCLC 2015
    • Type: Poster
    • Track: Thymoma, Mesothelioma and Other Thoracic Malignancies
    • Presentations: 1
    • +

      P1.08-007 - Programmed Cell Death 1 Ligand 1 (PD-L1) Expression in Thymoma (ID 46)

      09:30 - 09:30  |  Author(s): T. Nishi

      • Abstract
      • Slides

      Background:
      Programmed cell death 1 ligand-1 (PD-L1) has been reported to be expressed in various malignancies, and is considered to be a prognostic factor and an immunotherapeutic target. The aim of this study was to characterize PD-L1 expression in thymoma and statistical associations between this expression and clinical features.

      Methods:
      We reviewed formalin-fixed paraffin-embedded tissue specimens from 82 thymoma cases at Kurume University. PD-L1 expression was evaluated by immunohistochemistry (IHC). Statistical associations between PD-L1 expression and clinicopathological features were evaluated by using chi-square test and Fisher’s exact test. Disease-free survival (DFS) analysis, the end event of which is recurrence, was performed by the Kaplan-Meier method.

      Results:
      A total of 44 thymoma cases (54%) revealed high PD-L1 expression by IHC. No significant differences were observed between high and low PD-L1 expression with respect to sex (P = 0.938), age (P = 1.000), symptomatic myasthenia gravis (P = 0.471), anti-acetylcholine receptor antibody titer (P = 0.513), primary tumor size (P = 0.527), or curability (P = 0.620). However, high PD-L1 expression was statistically associated with Masaoka’s stage III/IV disease (P = 0.043) and WHO type B2 or B3 thymoma (P = 0.044). DFS after complete resection in high PD-L1 expression cases was significantly worse than that in low PD-L1 expression cases (P = 0.021). Figure 1Figure 2





      Conclusion:
      Characterization of PD-L1 expression in thymoma should enable more effective clinical approaches, including prognostic stratification of patients and use of anti-PD-L1 antibody immunotherapy.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.